Testosterone for Women: The Hormone Your Doctor Never Mentioned

If you have had a full hormonal work-up with your doctor, there is a reasonable chance it included estradiol and FSH — and a significant chance it did not include testosterone. Yet testosterone declines progressively in women from their late 20s onward, affects libido, energy, lean muscle maintenance, cognitive clarity, and bone density, and responds well to replacement when it is properly assessed and dosed. It is simply not part of the standard conversation most women are invited into.

This is a systemic gap. Testosterone has been categorised culturally and medically as a male hormone, and that categorisation has meant that its role in women has been under-researched, under-taught, and under-prescribed for decades. The result is that a significant proportion of women in their 40s and 50s are living with the effects of testosterone deficiency — and have never heard that this is a treatable condition.

What Testosterone Does in Women

Women's testosterone is produced primarily in the ovaries and adrenal glands. At peak reproductive age, women typically have about one-tenth to one-twentieth the testosterone level of men — but at that level, it plays an essential role in multiple systems. It is the primary driver of libido in women, more so than estrogen. It supports lean muscle mass and the body's ability to respond to resistance training. It has a direct effect on bone mineral density, independent of estrogen. And it plays a role in cognitive energy and mood stability that is distinct from estrogen's effects.

When testosterone declines — which happens progressively through the 30s and 40s, with a sharper drop in perimenopause — the symptoms are specific: libido that decreases in a way not explained by relationship factors; persistent fatigue that is not resolved by rest; increasing difficulty building or maintaining muscle despite consistent training; a flat, low-drive quality to energy and motivation that is different from depression but resembles it in some ways.

Why Most Women Are Never Tested

The standard hormone panel ordered by a PCP or OB-GYN in a perimenopausal work-up typically includes TSH, FSH, and sometimes estradiol. Testosterone is not on the standard order — which means that without a physician who is specifically looking for it, it goes unmeasured. The patient presents with libido loss and fatigue, gets a "normal" FSH result, and is told her hormones are fine. No one has tested the hormone most directly related to her presenting symptoms.

This is a systemic protocol problem, not individual negligence. The solution is to work with a physician who orders a complete panel and interprets it in the context of symptoms — not one who uses a standard screen designed for a different purpose.

What Proper Testosterone Therapy Looks Like for Women

Testosterone therapy for women uses significantly lower doses than for men — typically 1/10th to 1/20th of a male dose. Precision matters: too much produces masculinising effects (acne, hair changes, voice deepening), which are reversible but undesirable. Too little produces no benefit. The goal is to restore physiologic levels — the range the body maintained naturally during peak reproductive years — not to exceed them.

IHA's BHRT program includes testosterone assessment as a standard component of the complete hormone panel. Where deficiency is identified and treatment is clinically appropriate, dosing is individualized to laboratory results under physician oversight, with monitoring to confirm that levels reach the therapeutic range without exceeding it. This is a treatment with a meaningful quality-of-life benefit for many women — and one that most of them have never been offered, or even told was possible.

If persistent fatigue, low libido, and difficulty maintaining muscle are part of your current experience, and your doctor has told you your hormones are normal, it is worth asking specifically whether testosterone was included in that assessment. If it was not, the assessment was incomplete.

The Research Base for Testosterone in Women

The research literature on testosterone therapy in women is smaller than the literature on estrogen, partly because the pharmaceutical industry has not had the same incentive to fund large-scale trials for a hormone that is effective at very low doses and is therefore less commercially valuable. But the evidence that exists is consistent and clinically meaningful. A 2019 global consensus statement, endorsed by 11 major medical societies including the Endocrine Society and the International Society for the Study of Women's Sexual Health, concluded that there is sufficient evidence to support testosterone therapy for hypoactive sexual desire disorder in post-menopausal women, and acknowledged the emerging evidence for broader benefits including energy, mood, muscle mass, and cognitive function.

Studies specifically examining testosterone restoration in perimenopausal women — a different population from the post-menopausal women most commonly studied — show benefits across multiple domains. Lean muscle mass is better preserved in women receiving testosterone therapy during weight management interventions compared to controls. Bone mineral density shows additive benefit when testosterone is combined with estrogen compared to estrogen alone. Cognitive performance, particularly spatial processing and verbal memory, shows improvement in women receiving testosterone. These are not isolated findings from small studies. They represent a consistent pattern across multiple independent research groups.

What Women Are Not Being Told About Their Decline

The testosterone decline in women is gradual enough that most women do not identify a specific moment when it began. Instead, they notice at 42 or 44 that their energy is different from what it was at 37 — not dramatically lower, but less available, less reliable, requiring more effort to sustain. They notice that their interest in exercise, which was intrinsically motivated, has become something they push themselves to do rather than something they want to do. They notice that their libido, which they may attribute to relationship factors or stress, has a physiological flatness that no amount of relationship work or life simplification changes.

These changes are attributed to age, stress, life demands, and the general heaviness of being a woman in midlife managing multiple demanding roles. The specific hormonal contribution — declining testosterone affecting the motivational and drive-related brain systems it supports — is rarely identified because no one has measured it and no one has told the patient it was happening. By the time the decline is severe enough to produce clearly abnormal lab values, the patient may have been attributing the symptoms to everything except their actual cause for five or more years.

The Assessment and Treatment Process

Identifying and addressing testosterone deficiency in women requires a physician who is specifically looking for it — which means ordering a panel that includes total and free testosterone, SHBG (which affects how much testosterone is biologically active), and DHEA-S (a precursor that the body converts to testosterone). This is not a standard panel. It needs to be ordered explicitly by a clinician who is taking the possibility of testosterone deficiency seriously.

Treatment for confirmed deficiency uses low-dose transdermal testosterone — typically a cream or gel applied to the skin — at doses calibrated to place levels in the physiological range for women (25 to 80 ng/dL total testosterone, depending on the clinical context). This is not the same as testosterone therapy for men. It is a fraction of male dosing — but that fraction is precisely what women need to restore the levels their body maintained in their 30s.

Monitoring is essential. Labs at three months confirm that levels have reached the intended range — not too low (no benefit) and not too high (masculinising effects). Subsequent monitoring at six to twelve months ensures the dose remains appropriate as the patient's own production changes over time. IHA's BHRT program includes testosterone assessment as a standard component and addresses deficiency where it is identified — under physician oversight with the lab monitoring that appropriate treatment requires.

Testosterone and the Combined Hormone Protocol

Testosterone is rarely the first hormone discussed when a woman begins exploring hormone therapy. The clinical conversation typically starts with estrogen — vasomotor symptoms, vaginal health, bone density — and progesterone as its necessary companion for endometrial protection. Testosterone enters the picture later, if at all, often framed narrowly as a libido treatment. This framing underestimates the clinical scope of testosterone's role in a comprehensive BHRT protocol and leads to programs that address two of the three primary hormones while leaving the third inadequately managed.

The additive effects of a combined three-hormone protocol on bone density are clinically meaningful and not replicable by estrogen alone. Estrogen primarily inhibits osteoclast activity — it slows bone resorption. Testosterone, through androgen receptor activity in osteoblasts, directly stimulates bone formation. These are distinct mechanisms that work synergistically: estrogen preserves existing bone while testosterone contributes to new bone deposition. Studies comparing women on estrogen-only therapy to women on combined estrogen-testosterone protocols have demonstrated higher bone mineral density gains in the combined group, a finding with direct implications for women in their forties and fifties who are in the early phases of bone loss before significant deficits are established. Starting a combined protocol during perimenopause — before substantial bone density loss has occurred — maximizes the long-term protective effect of both mechanisms operating together.

The same additive logic applies to muscle preservation. The lean mass loss associated with declining estrogen during perimenopause has received increasing attention, particularly in the context of GLP-1 therapy, where the risk of losing lean tissue alongside fat is well documented. Testosterone's anabolic effect on skeletal muscle is established in men and increasingly documented in women: it supports muscle protein synthesis, increases the proportion of type II muscle fibers (which are responsible for strength and power), and appears to enhance the anabolic response to resistance training. A woman on a GLP-1 program who is also optimizing testosterone is creating a more favorable body composition environment than a woman managing GLP-1 side effects without addressing hormonal decline. The interaction is additive, not redundant.

Cognitive function, as discussed in the brain fog post, involves both estrogen and testosterone through partially overlapping but distinct mechanisms. Estrogen's contribution is primarily hippocampal — verbal memory, encoding, neuroprotection. Testosterone's contribution involves prefrontal cortex function, processing speed, spatial cognition, and motivational drive. A comprehensive approach to cognitive preservation during perimenopause addresses both hormonal contributions. A protocol that restores estrogen to a therapeutic range while leaving testosterone in the lower quartile of the female reference range is achieving partial cognitive optimization, not complete restoration. Women who report that their brain fog has improved on BHRT but that motivational flatness or processing speed problems persist should ask specifically whether testosterone has been assessed and addressed.

Addressing testosterone in isolation — as many wellness providers and direct-to-consumer platforms do, offering testosterone creams without estrogen or progesterone assessment — creates a different problem. Testosterone is aromatized to estrogen in peripheral tissues. A woman receiving supraphysiologic testosterone without estrogen monitoring may accumulate more estradiol than is clinically appropriate, potentially without the progesterone protection that estrogen exposure requires. Conversely, a woman with documented estrogen deficiency who receives testosterone supplementation without concurrent estrogen restoration is receiving incomplete treatment for her hormonal state. The hormones interact: addressing them individually, in isolation from each other, is not equivalent to addressing them comprehensively within a monitored protocol.

Monitoring a combined three-hormone protocol involves more data points than a single-hormone approach. Follow-up labs at eight to twelve weeks should include estradiol, total and free testosterone, SHBG, progesterone, and DHEA-S — not just the primary prescribed hormone. SHBG is particularly relevant for testosterone monitoring: high SHBG binds free testosterone and can render a numerically adequate total testosterone level clinically insufficient. A provider who monitors only the administered hormone while leaving the others unmeasured is not actually managing the interaction. For women who want to understand the full picture of what assessment and monitoring should involve, the post on questions to ask any hormone clinic provides a complete evaluation framework. And for context on how testosterone fits into the broader story of what women are not typically told about their hormonal health, the post on the ten-year hormone window makes the case for starting the complete conversation now rather than waiting for the picture to become more urgent.

The practical implication of this analysis is that a clinical intake for a combined hormone program should assess all three hormones — estrogen, progesterone, and testosterone — at baseline, even if only one or two are initially prescribed. Knowing the full baseline picture allows the prescribing physician to design a phased protocol: beginning with the most clinically urgent deficiency, monitoring the response, and adding the next component at the appropriate point. A woman whose estrogen and progesterone are more severely deficient than her testosterone may begin there and add testosterone at the three-month visit when the initial protocol is stable. This phased approach is clinically sound and practically manageable — it does not require doing everything simultaneously but does require having a complete picture from the start. A clinic that assesses only the hormone it plans to prescribe is not providing the clinical foundation for a comprehensive protocol; it is providing a fragment of one. Understanding the full baseline is what makes a phased approach intelligent rather than arbitrary.

Getting Testosterone Assessment and Treatment Right

The practical barrier to testosterone assessment for women is that most standard hormonal panels do not include it — and the physicians most likely to be reviewing those panels are OB-GYNs or primary care physicians who may not have a treatment protocol ready even if deficiency is identified. The absence from the standard panel reflects the historical absence of FDA-approved testosterone products for women, which created a regulatory and commercial gap that has never been properly filled. The clinical evidence for testosterone's benefits in women is not in dispute. The treatment infrastructure simply developed in a piecemeal way.

Physician practices with specific training in hormonal optimization have been filling this gap for years through compounded testosterone preparations — typically transdermal creams or gels dosed at a fraction of male levels, calibrated to the woman's baseline and monitored with follow-up labs to confirm appropriate levels without supraphysiological dosing. BHRT at IHA includes testosterone assessment and prescribing as a standard component of the full hormonal evaluation, because leaving it untreated in women who are deficient produces predictable consequences for energy, muscle, libido, and cognitive drive that none of the other treatments in the protocol fully compensate for. Starting with a comprehensive assessment is the first step toward knowing where you actually stand.

The Long View on Testosterone Therapy

Women who start testosterone therapy with realistic expectations and appropriate monitoring tend to have sustained, positive clinical experiences. The changes are not dramatic in the way that pharmaceutical marketing sometimes implies — there is no overnight transformation. What most women describe over the course of three to six months is a gradual return of the energy, drive, and physical capability that had been diminishing so gradually they barely registered it as a loss until it began returning. The libido improvement, where it occurs, is often described as a restoration of something that had faded rather than an amplification beyond prior experience. The lean mass preservation and the improved response to resistance training are measurable on follow-up body composition assessment. The combination of these changes — each modest in isolation, together significant — is what the clinical evidence supports and what properly managed therapy produces. IHA's approach to testosterone for women is built on this realistic clinical picture, and the monitoring at three and six months provides the data to confirm it.